Clinical trial
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
NCT00044564 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044564 |
|---|---|
| Title | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma |
| Official title | An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Bay 59-8862 |
| Enrollment | 54 |
| Start date | Dec 1, 2001 |
| Completion | Jan 1, 2003 |
| First posted | Sep 4, 2002 |
| Last update posted | Dec 19, 2014 |
| Countries | Canada, France, Germany, Netherlands, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: